Yarrow Bioscience (YARW) Cash & Equivalents (2016 - 2026)

Yarrow Bioscience (YARW) has 11 years of Cash & Equivalents data on file, last reported at $24.6 million in Q1 2026.

• Quarterly Cash & Equivalents fell 12.68% year-over-year to $24.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.6 million (down 12.68% YoY) and the FY2025 annual result came in at $24.0 million, up 20.58% from the prior year.
• Cash & Equivalents climbed to $24.6 million in Q1 2026, from $24.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $50.5 million in Q1 2022 to a low of $54000.0 in Q3 2023.
• A 5-year average of $20.8 million and a median of $21.3 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents sank 99.87% — and 2024, when it jumped 36800.0%.
• Tracing YARW's Cash & Equivalents over 5 years: stood at $67000.0 in 2022, then declined by 19.4% to $54000.0 in 2023, then jumped by 36800.0% to $19.9 million in 2024, then climbed by 20.58% to $24.0 million in 2025, then climbed by 2.51% to $24.6 million in 2026.
• The last three Cash & Equivalents figures came in at $24.6 million (Q1 2026), $24.0 million (Q4 2025), and $22.0 million (Q2 2025), per Business Quant data.